首页 › 基金 › SILVERARC CAPITAL MANAGEMENT, LLC › ASND
SILVERARC CAPITAL MANAGEMENT, LLC 对 ASND 的持仓历史
ASCENDIS PHARMA A/S · 医疗保健
SILVERARC CAPITAL MANAGEMENT, LLC 在 Q3 2026 的 13F 申报中披露持有 ASND(ASCENDIS PHARMA A/S)152,175 股,市值约 US$34.7M,约占其申报组合的 4.42%,在其申报持仓中市值排名第 7 位。 SILVERARC CAPITAL MANAGEMENT, LLC 最近 9 个申报季度中有 9 个季度披露了 ASND 持仓,最早可追溯至 Q3 2024。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
SILVERARC CAPITAL MANAGEMENT, LLC 对 ASND 的持仓演变
SILVERARC CAPITAL MANAGEMENT, LLC 于 Q3 2024 首次披露 ASND 持仓:5,000 股(约 US$747K)。 该持仓在 Q2 2026 达到峰值 206,234 股,市值约 US$55.0M。 在 9 次申报中,SILVERARC CAPITAL MANAGEMENT, LLC 5 次增持、3 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 152,175 股、市值约 US$34.7M,环比减持 -54,059 股。。 持仓曾出现大幅变动:Q4 2024 增持约 930% (随后一个季度股价上涨 13%)、Q1 2026 增持约 153% (随后一个季度股价上涨 17%)、Q2 2026 增持约 65% (随后一个季度股价下跌 15%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2024 | 5.00K | $746.55K | 新进 |
| Q4 2024 | 51.49K | $7.09M | 增持 |
| Q1 2025 | 75.75K | $11.81M | 增持 |
| Q2 2025 | 86.55K | $14.94M | 增持 |
| Q3 2025 | 53.55K | $10.65M | 减持 |
| Q4 2025 | 49.23K | $10.50M | 减持 |
| Q1 2026 | 124.66K | $28.51M | 增持 |
| Q2 2026 | 206.23K | $55.01M | 增持 |
| Q3 2026 | 152.18K | $34.67M | 减持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 ASND 与 13F 数据
ASND(ASCENDIS PHARMA A/S)属于医疗保健行业。我们追踪的基金中还有 37 只申报持有 ASND,申报仓位最大的包括:RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 ASND 的基金
- RA CAPITAL MANAGEMENT, L.P. 10.28M 股 · $2.74B · Q2 2026
- T. Rowe Price Investment Management, Inc. 6.75M 股 · $1.80B · Q2 2026
- Avoro Capital Advisors LLC 5.11M 股 · $1.36B · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 5.13M 股 · $1.17B · Q3 2026
- Jupiter Topco LLC 3.65M 股 · $973.38M · Q2 2026
- Artisan Partners Limited Partnership 2.08M 股 · $474.58M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.16M 股 · $310.39M · Q2 2026
- Vestal Point Capital, LP 375.00K 股 · $100.02M · Q2 2026
- Tri Locum Partners LP 258.74K 股 · $69.01M · Q2 2026
- ORBIMED ADVISORS LLC 244.46K 股 · $65.20M · Q2 2026
- PFM Health Sciences, LP 233.17K 股 · $62.19M · Q2 2026
- Frazier Life Sciences Management, L.P. 225.16K 股 · $60.05M · Q2 2026
更多关于 SILVERARC CAPITAL MANAGEMENT, LLC
常见问题
How long has SILVERARC CAPITAL MANAGEMENT, LLC held ASND?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ASND holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in ASND?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 152.18K shares of ASND (ASCENDIS PHARMA A/S), valued at $34.67M, representing 4.42% of its reported portfolio and ranking #7.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling ASND?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in ASND. The position peaked in Q2 2026 at 206.23K shares.
Which other funds hold ASND?
Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.